You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 63 No. 7, July 2006 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Viral Infections
 •Pain
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Improvement of Postherpetic Neuralgia After Treatment With Intravenous Acyclovir Followed by Oral Valacyclovir

Dianna Quan, MD; Barbara N. Hammack, PhD; John Kittelson, PhD; Donald H. Gilden, MD

Arch Neurol. 2006;63:940-942. Published online May 8, 2006 (doi:10.1001/archneur.63.7.noc60049).

Background  Postherpetic neuralgia (PHN) is a complication of shingles (herpes zoster), a painful rash due to varicella-zoster virus reactivation. Studies of patients with PHN and zoster sine herpete (radicular pain without rash) support the notion that low-grade viral ganglionitis contributes to pain. If chronic pain reflects active infection, then antiviral therapy may help patients with PHN.

Objective  To determine whether antiviral treatment helps reduce PHN-associated pain.

Design  Prospective, open-label phase I/II clinical trial.

Setting  Tertiary care university hospital.

Patients  Fifteen patients with moderate to severe PHN.

Interventions  Intravenous acyclovir at a dosage of 10 mg/kg every 8 hours for 14 days followed by oral valacyclovir at a dosage of 1000 mg 3 times per day for 1 month.

Main Outcome Measure  Numeric Rating Scale for Pain score.

Results  As defined by a decrease of 2 or more points on the Numeric Rating Scale for Pain, 8 (53%) of 15 patients reported improvement.

Conclusion  Clinical improvement reported by most of our patients warrants further investigation in a larger, randomized, double-blind, placebo-controlled trial.


Author Affiliations: Departments of Neurology (Drs Quan, Hammack, and Gilden), Preventive Medicine and Biostatistics (Dr Kittelson), and Microbiology (Dr Gilden), University of Colorado Health Sciences Center, Denver.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Persistence of Varicella Zoster Virus DNA in Saliva After Herpes Zoster
Nagel et al.
The Journal of Infectious Disease 2011;204:820-824.
ABSTRACT | FULL TEXT  

Increased Risk of Guillain-Barre Syndrome following Recent Herpes Zoster: A Population-Based Study across Taiwan
Kang et al.
Clinical Infectious Diseases 2010;51:525-530.
ABSTRACT | FULL TEXT  

Effect of High versus Low Oral Doses of Valacyclovir on Herpes Simplex Virus-1 DNA Shedding into Tears of Latently Infected Rabbits
Kumar et al.
IOVS 2010;51:4703-4706.
ABSTRACT | FULL TEXT  

Recommendations for the Management of Herpes Zoster
Dworkin et al.
Clinical Infectious Diseases 2007;44:S1-S26.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.